[Cutaneous XXXX associated with cetuximab treatment in metastatic colorectal cancer].

@entity1 @entity137 @entity5 @entity31351 @entity9252 @entity158 @entity2024
OBJECTIVE: To evaluate the impact and type of side-effects in @entity1 treated with cetuximab and provide a description of the general measures and treatment. METHODS: Retrospective safety study. We included all @entity1 that received cetuximab from January to December 2009. All information was obtained from the Pharmacy and Oncology Department's Access databases and reviewed the @entity1 's medical history. All data was registered in an Excel workbook. @entity137 was graded by the current National @entity5 Institute-Common @entity137 Criteria (NCI-CTC). RESULTS: During the study period 43 @entity1 received treatment with cetuximab. @entity31351 was present in 30 of the cases (69.8%): 14 @entity1 with grade 1 (48.3%), 13 with grade 2 (44.8%) and 3 with grade 3 (10.3%). These adverse effects appeared in a median of seven (4-28) days. In a median of 40 (20-56) days, ten @entity1 (23.3%) presented xerosis, and three (7%) suffered @entity158 in hands and feet after a median of 28 (21-35) days. @entity9252 was present in two @entity1 after a median of 42 (35-49) days. Finally, an alteration in hair growth was observed in two @entity1 with overgrowth of facial hair and one @entity1 with overgrowth of the eyelashes. Five @entity1 presented important @entity2024 . Three infusion reactions occurred. A grade-based treatment algorithm was used for all @entity1 that presented cutaneous @entity137 . CONCLUSIONS: A considerable number of @entity1 treated with cetuximab develop dermatological side-effects which left untreated could represent a threat to the efficacy of the therapy. Therefore effective management is mandatory, @entity1 education and immediate treatment based on a grade-based algorithm to alleviate symptoms is necessary, so that @entity1 compliance is guaranteed.
